Visionary Leader in the Pharmaceutical Industry

1. www.newdelhireview.com Nov 2024 | Issue 02 Leading the Indian Pharmaceutical Renaissance

4. Editor’s Note Editor

5. A TRANSFORMATIVE FORCE INSPIRING THE NEXT GENERATION OF HEALTHCARE LEADERS Indian pharma prowess onto the global stage owes its thanks to the foresight and determination of leaders like Dr Pradeep Kumar Jain, the mightyFounder and Director of Ananta Medicare Ltd. With his over 25 years of experience, Dr Pradeep symbolizes a pharma professional who has innovation, resilience, and strategic acumen, thus, leading Ananta Medicare to be crowned as a global healthcare giant. A journey that began in Ukraine, Dr Pradeep who was a modest pharmaceutical trader deep dived into the education. He gave himself a strong educational foundation, including a Bachelor’s in Production Management, an MBA, and a PhD. Then he decided to combine his technical expertise with business acumen to revolutionize the pharmaceutical industry. His innate entrepreneurial spirit and a keen eye for emerging trends sowed the seeds of Ananta Medicare in 1999, a company now grown into a business excellence of manufacturing and exporting pharmaceuticals, nutraceuticals, Ayurvedic, herbal, and cosmetic products. Guided precisely by the vision of Dr Pradeep, his company Ananta Medicare operates three state-of-the-art manufacturing plants in India. WHO, EU GMP and US FDA compliant, these facilities reflect his commitment to quality and innovation ensuring the company stays ahead in the pharmaceutical wave. Dr Pradeep, through his global vision, has helped Ananta Medicare to expand its markets from the USA, UK, Europe, and other countries of the world. Strategic collaboration and diversified product portfolio with the company have enabled it to approach global healthcare needs. His philosophy, "Education is the bedrock of innovation," drives his continuous research and development, fostering new technologies and products that meet the evolving health demands. Apart from business, Dr Pradeep promotes corporate social responsibility by advocating sustainable practices and enhancing access to affordable healthcare, especially in underdeveloped areas. His numerous awards include the State Level Export Award and Ayush Premium Mark, which reflect his commitment to excellence and social impact. As Dr Pradeep captains Ananta Medicare into the future, his legacy as a transformative force in the pharmaceutical industry continues to inspire the next generation of healthcare leaders. Depicted in the following pages of this special New Delhi Review’s edition, ‘Visionary Leader in the Pharmaceutical Industry,’Dr Pradeep Kumar Jain’s journey stands as a testament to the power of vision, perseverance, and a dedication to improving global health outcomes. Gaurav PR Wankhade Managing Editor

6. www.newdelhireview.com Editor-in-Chief Pooja M. Bansal Managing Editor Gaurav PR Wankhade Assisting Editor Prajakta Zurale Visualizer Sandeep Tikode Art & Design Director Rahul Shinde Art & Design Editor Sarita Bhagat Asst. Designers Nagaraj Patil & Satish Garde sales@newdelhireview.com NOV, 2024 Corporate Offices: Insights Success Media and Technology Pvt. Ltd. Survey No.133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027 Phone - India: +91 8793630422/24 Email: info@insightssuccess.in For Subscription: www.insightssuccess.in Vice President Swapnali Vasaikar Asst. Vice President Asst. Manger Sr. BDE Siddhi Bhosale BDE Sneha Kasabe Tejaswini Whaval Nitin Patil Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - (614)-602-1754 Email: info@insightssuccess.com For Subscription: www.insightssuccess.com Technical Head Prachi Mokashi Technical Specialist Rajeshwari Avhad Digital Marketing Manager Sagar Lahigade SME-SMO Executive Prashant Rathod Circulation Manager Tanaji Fartade 250/- https://twitter.com/newdelhireview.com Follow us on : www.facebook.com/NewDelhiReview/ www.instagram.com/newdelhireviewmagazine/ We are also available on Copyright © 2024 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success Media and Technology Pvt. Ltd. Reprint rights remain solely with Insights Success. Printed and Published by Insights Success Media and Technology Pvt. Ltd. RNI NUMBER: MAHENG/2018/75953

7. Subscribe Today Read it First Stay in touch. New Delhi Review Get New Delhi Review Magazine in print, & digital on www.newdelhireview.com Subscribe to CORPORATE OFFICE Insights Success Media and Technology Pvt. Ltd. Survey No.133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027 Phone - India: +91 7410079881/ 82/ 83/ 84/ 85 Email: info@insightssuccess.in For Subscription: www.insightssuccess.in www.newdelhireview.com

8. The Hallmarks of a Visionary Leader Dr Pradeep Kumar Leading the Indian Pharmaceutical Renaissance “ By investing in infrastructure benchmark for excellence in and fostering a culture of pharmaceutical manufacturing. continuous improvement, we positioned Ananta Medicare as a

9. Dr Pradeep Kumar Jain Founder and Director Ananta Medicare Ltd

10. I ndia's impressive evolution into a global pharmaceutical leader in the wake of the COVID-19 pandemic highlights the vision, resilience, and innovation of its leadership. During this challenging time, a group of exceptional leaders emerged, steering the Indian pharma sector through significant growth and obstacles. Championed Public Health Initiatives: Leaders like Dr Pradeep Kumar Jain supported public health initiatives and social responsibility programs, demonstrating their commitment to improving healthcare access and outcomes. Dr Pradeep Kumar Jain stands as a towering figure in the realm of pharmaceuticals-powered healthcare, and his journey is emblematic of resilience, astute business strategies, and an unwavering commitment to excellence. With over 25 years of experience, Dr Pradeep Kumar Jain has transformed his initial foray into the pharmaceutical sector into a global powerhouse, establishing Ananta Medicare as a major player in the manufacturing and export of pharmaceuticals. His journey from a small-time trader in Ukraine to a respected leader in the pharmaceutical field is a testament to his vision, strategic acumen, and unwavering commitment to quality and excellence. In an ever-evolving landscape of contemporary health- conscious times, few individuals exemplify the spirit of innovation and leadership as profoundly as Dr Pradeep Kumar Jain, the Founder and Director of Ananta Medicare Ltd, a global conglomerate employing a team of 660 people, with its presence in Ukraine, India, Russia, Uzbekistan, UK, USA, UAE, and Philippines. Dr Pradeep Kumar Jain says, “We are a close-knit, hardworking and active team of professionals who are dedicated to their work and focused on a common result.” During the COVID-19 pandemic, India's pharmaceutical industry played a crucial role in addressing the global health crisis. Indian manufacturers rapidly scaled up the production of essential medicines and medical devices, ensuring a steady supply to both domestic and international markets. This response showcased the industry's capacity, flexibility, and commitment to global health. Dr Pradeep Kumar Jain’s narrative chronicles the transformation of a small pharmaceutical trader into a global industry titan, reshaping markets and empowering communities along the way. Early Beginnings and Entrepreneurial Spirit Dr Pradeep Kumar Jain’s educational background laid a strong foundation for his future endeavours, equipping him with the knowledge and skills necessary to navigate the complex pharmaceutical landscape. He began his academic journey with a Bachelor’s degree in Production Management from Kharkiv Polytechnical University in 1997. This technical expertise provided him with a solid understanding of manufacturing processes, which would later prove invaluable in his career. His early education instilled in him a keen awareness of the intricacies involved in production, allowing him to appreciate the importance of efficiency and quality in manufacturing—a principle that would become central to his work at Ananta Medicare. The Rising Pharma Giant The Indian pharma renaissance was fuelled by a cadre of visionary leaders like Dr Pradeep Kumar Jain, who recognized the industry's potential and took bold steps to capitalize on it. They: Invested in Research and Development: Leaders like Dr Pradeep Kumar Jain prioritized research and development, fostering innovation and developing new products and technologies. Embraced Global Partnerships: They forged strategic alliances and partnerships with international pharmaceutical companies, expanding market access and learning from global best practices. Recognizing the need for further education to enhance his business acumen, Dr Pradeep Kumar Jain pursued a Master of Business Administration from Simon Kuznets Kharkiv National University of Economics in 2015. This program equipped him with essential business skills and insights into market dynamics, empowering him to make informed strategic decisions. His MBA experience not only broadened his understanding of business operations but also honed his leadership capabilities, preparing him for the challenges of running a global pharmaceutical enterprise. Focused on Quality and Regulatory Compliance: They implemented stringent quality standards and regulatory compliance measures to ensure the safety and efficacy of Indian-made products. Nurtured Talent: They invested in talent development, training, and education to build a skilled workforce capable of meeting the demands of a growing industry.

11. “ Visionary Leader in the Pharmaceutical Industry Every challenge I faced was an stepping stones. opportunity to learn and grow. It was this mindset that propelled me forward, turning obstacles into

12. “ Education is the bedrock of innovation; it empowers us to challenge the status quo and drive meaningful change.

13. Dr Pradeep Kumar Jain has recently completed his PhD at the same institution. His continuous pursuit of knowledge reflects his belief in lifelong learning and his desire to stay at the forefront of industry development. This academic rigour has not only enriched his personal growth but has also contributed significantly to the strategic direction of Ananta Medicare. As he often states, "Education is the bedrock of innovation; it empowers us to challenge the status quo and drive meaningful change." This philosophy has guided him throughout his career, influencing the way he approaches business challenges and opportunities. In 2008, Jain's entrepreneurial talents soared with the launch of Ananta Medicare Limited. As the primary promoter and investor, he directed the company toward exceptional growth, utilizing his expertise to build a strong foothold in both domestic and international markets. Under his guidance, Ananta Medicare became a leading manufacturer and exporter of pharmaceutical and healthcare products, receiving recognition for its dedication to quality and innovation, showcasing his visionary leadership and strategic insight. Ananta Medicare operates three state-of-the-art manufacturing plants in India, adhering to stringent WHO standards and regulatory compliance, including EU GMP and US FDA regulations. These facilities are equipped with cutting-edge technology, ensuring efficient production processes while maintaining the highest quality standards. Dr Pradeep Kumar Jain’s commitment to innovation is evident in the company's continuous investment in advanced manufacturing capabilities, positioning Ananta Medicare as a leader in quality and compliance within the pharmaceutical sector. In the year 2000, Dr Pradeep Kumar Jain embarked on his entrepreneurial voyage as a modest pharmaceutical trader in Ukraine. Fuelled by ambition and a keen eye for opportunities, he swiftly carved a niche for himself in the competitive landscape. His innate ability to analyze markets and discern trends laid the foundation for his future successes, setting him apart as a visionary leader from the outset. As he reflects on his journey, he notes, “Every challenge I faced was an opportunity to learn and grow. It was this mindset that propelled me forward, turning obstacles into stepping stones.” Visionary Leadership and Global Expansion Dr Pradeep Kumar Jain’s educational background, combined with his early entrepreneurial experiences, equipped him with a unique perspective on the pharmaceutical industry. He understood the importance of not only producing high-quality products but also ensuring that these products met the evolving needs of consumers. As Dr Pradeep Kumar Jain states, “Our purpose is providing patients and specialists in the field of medicine and pharmacy with high-quality medical products in accordance with modern healthcare standards,” this understanding became the cornerstone of Ananta Medicare's mission, guiding the company's growth and expansion into international markets. Dr Pradeep Kumar Jain’s visionary leadership is characterized by a strategic focus on expanding Ananta Medicare's footprint in key markets such as the United States, United Kingdom, and Europe. His ability to identify emerging trends and adapt to changing market dynamics has been pivotal in driving the company's growth. Dr Pradeep Kumar Jain’s foresight in recognizing the potential of international markets has allowed Ananta Medicare to establish a strong presence globally, with registered offices in New Delhi, London, Miami, Dubai, Kharkiv, Tashkent, Almaty, and Manila. Under Dr Pradeep Kumar Jain’s guidance, Ananta Medicare has forged strategic partnerships with various global buyers, including prominent companies in Ukraine, India, Russia, Uzbekistan, the UAE, and the Philippines. These collaborations have not only enhanced the company's market reach but have also facilitated knowledge exchange and best practices in pharmaceutical manufacturing and distribution. Building a Healthcare Giant In 1999, Dr Pradeep Kumar Jain established Ananta Limited, which later became Ananta Medicare Ltd. Under his visionary leadership, the company has transformed from humble beginnings into a significant manufacturer and exporter of pharmaceuticals, Ayurvedic, herbal, nutraceutical, and cosmetic products. Jain's strategic emphasis on international expansion, especially in Eastern Europe and CIS markets, has played a key role in diversifying the company’s product range and strengthening its global presence.

14. Commitment to Innovation and Excellence Dr Pradeep Kumar Jain’s dedication to quality is reflected in Ananta Medicare's active participation in research programs and ongoing product range expansion, which address various areas of preventative medicine and wellness. His leadership style emphasizes the importance of building a strong professional team. He believes that a company’s success is intrinsically linked to the capabilities and expertise of its workforce. By fostering a culture of continuous improvement and professional development, Dr Pradeep Kumar Jain ensures that Ananta Medicare attracts and retains top talent in the industry. This focus on human capital development not only enhances the company's operational efficiency but also strengthens its competitive advantage in the global market. Dr Pradeep Kumar Jain’s commitment to innovation is a driving force behind Ananta Medicare's success. He prioritizes the establishment of cutting-edge facilities and state-of-the-art manufacturing processes, ensuring that the company remains at the forefront of technological advancements in the pharmaceutical industry. One of Dr Pradeep Kumar Jain’s key initiatives was the diversification and expansion of Ananta Medicare's product portfolio. By fostering collaborations with renowned pharmaceutical companies and prioritizing quality production standards, he broadened the company's offerings, catering to diverse market segments and meeting evolving consumer demands. His visionary approach ensured that Ananta Medicare remained at the forefront of innovation, continually introducing new products and pioneering advancements in healthcare. Through these strategic initiatives, Dr Pradeep Kumar Jain has positioned Ananta Medicare as a leader in the pharmaceutical sector, driving growth and innovation while maintaining a steadfast commitment to quality and excellence.

15. “ By fostering collaborations with offerings, catering to diverse market renowned pharmaceutical companies segments and meeting evolving and prioritizing quality production consumer demands. standards, we broadened our Commitment to Corporate Social Responsibility and Ethical Practices recognizing its potential for growth and opportunity. With meticulous planning and strategic execution, he laid the groundwork for Ananta Medicare's entry into the US market, securing regulatory approvals and forging partnerships with key stakeholders. His hands-on approach and dedication to market expansion underscore his relentless pursuit of success on a global scale. Beyond business success, Dr Pradeep Kumar Jain is deeply committed to social responsibility and ethical practices within the pharmaceutical industry. He recognizes the critical role that healthcare plays in society and strives to ensure that Ananta Medicare contributes positively to community health and well-being. Dr Pradeep Kumar Jain advocates for sustainable practices in manufacturing and distribution, emphasizing the importance of minimizing environmental impact while delivering high-quality healthcare solutions. Through these strategic initiatives, Dr Pradeep Kumar Jain has enhanced Ananta Medicare's manufacturing capabilities and opened new avenues for growth in international markets, solidifying the company's reputation as a leader in the pharmaceutical industry. Future Outlook and Legacy: Proliferating a Pharmaceutically Advanced Tomorrow Dr Pradeep Kumar Jain’s vision extends to improving access to essential medicines and healthcare products, particularly in underserved regions. By expanding Ananta Medicare's reach and offering affordable healthcare solutions, he aims to make a meaningful difference in the lives of individuals and communities. Dr Pradeep Kumar Jain’s journey from a small-time trader to a visionary leader in the pharmaceutical industry is a remarkable testament to his resilience, strategic thinking, and commitment to excellence. As the Founder and Director of Ananta Medicare Ltd, he has successfully transformed the company into a global healthcare giant, setting new standards for quality, innovation, and social responsibility. As Dr Pradeep Kumar Jain continues to chart new territories and push the boundaries of innovation, his legacy as a visionary leader in the pharmaceutical industry is etched in stone. With his unwavering dedication to advancing healthcare and improving patient outcomes, Dr Pradeep Kumar Jain continues to inspire the next generation of leaders in the pharmaceutical sector. Investment in Innovation and American Expansion Recognizing the pivotal role of manufacturing excellence in sustaining growth, Dr Pradeep Kumar Jain spearheaded the establishment of three state-of-the-art manufacturing plants in Sri Ganganagar, Rajasthan. Built to European standards and equipped with cutting-edge technology, these facilities exemplify Dr Pradeep Kumar Jain’s unwavering commitment to quality and compliance. By investing in infrastructure and fostering a culture of continuous improvement, he positioned Ananta Medicare as a benchmark for excellence in pharmaceutical manufacturing. As Ananta Medicare forges ahead, Dr Pradeep Kumar Jain’s vision and leadership will undoubtedly play a pivotal role in shaping the future of healthcare in India and beyond. With a steadfast commitment to excellence, integrity, and social responsibility, In a testament to his visionary leadership, Dr Pradeep Kumar Jain set his sights on the American market,

16. “ he remains an inspiration to aspiring entrepreneurs and industry peers alike. His journey serves as a testament to the transformative power of determination, perseverance, and unwavering vision. We are a close-knit, common result. hardworking and active team of professionals who are dedicated Awards and Achievements to their work and focused on a Dr Pradeep Kumar Jain was awarded numerous certificates of honour and gratitude from the Ministry of Health and the Regional State Administration for his high professionalism and significant personal contribution to implementing modern state policy in the field of healthcare, charitable organizations, and foundations for helping children, large families, and those in need. The company and its management have won many awards and titles: assessment by a third party in compliance with regulatory requirements. ● Import Export Award – gold andsilver medals in the ranking of exporting enterprises. ● State Level Export Award/Highest Growth on Chemical, Pharmaceuticals & Allied Products – for the highest export growth rate. ● Two Star Export House – for export volumes. ● Rajasthan Jewel of the Industry’s Award– for presenting the best commercial practices. ● Ayush Premium Mark – for premium product quality for domestic and international markets based on quality Thus, through his strategic initiatives and innovative approaches, Dr Pradeep Kumar Jain has not only enhanced Ananta Medicare has also opened new avenues for growth in international markets, solidifying the company's reputation as a leader in the pharmaceutical industry. 's manufacturing capabilities but

18. Good Health Can't Wait! 16 | www.newdelhireview.com 16 | Nov, 2024

19. How Can India Increase Research in the Pharmaceutical Industry? G of life. The pharmaceutical industry serves an important function in securing treatments and cures for humanity, but its best uses only unfold if there is a powerful foundation of research. This is not so in the case of India, considered to be a leading developer of generic medicines, because this demographic, though holds a respectable place in the rank list but as far as development is concerned, remains grossly underdeveloped. ood health forms the backbone of progress for individuals and society. It allows people to contribute meaningfully and enjoy a better quality "Good Health Can't Wait!" - This statement underlines the sense of urgency to improve health systems. The increasing population in India, the rising prevalence of lifestyle diseases, and the demand for affordable healthcare clearly highlight that pharmaceutical research needs improvement. Innovation in this field will help in addressing national needs and also strengthen India's position as a global healthcare provider. Building a robust research ecosystem requires investments, collaborations, and forward-thinking policies. This approach can help India ensure that good health truly cannot wait. Increase Funding for Research One of the major challenges facing pharmaceutical research in India is underfunding. Companies are not willing to invest in long-term projects due to high costs and risks. The government can make up for this by increasing its financial support and creating incentives for private players. Tax breaks, grants, and subsidies for research projects can encourage businesses to allocate more resources to innovation. 17 | www.newdelhireview.com Nov, 2024

20. India can also set up a national pharmaceutical research fund to support groundbreaking projects. Public-private partnerships can gather resources, knowledge, and technology for faster outcomes. By combining their efforts, stakeholders also cut costs and share risks, making research more sustainable. Setting up pilot-scale manufacturing facilities in these hubs can help researchers move from experiments to market- ready products. World-class infrastructure will also attract international companies to invest in Indian research, bringing new opportunities and expertise. Train and Retain Skilled Researchers Build Stronger Industry-Academia Links Skilled researchers drive pharmaceutical innovation. India needs to invest in training programs and scholarships to build a talented workforce. Workshops on advanced techniques and collaboration with global institutions can improve the skills of Indian researchers. Collaborations between universities and pharmaceutical companies are essential for boosting research. The academia offers theoretical knowledge and talent pool, while the industry offers practical experience and advanced resources. The partnership will fill in the gap between ideas and their applications. It is equally important to retain talent. This can be achieved by providing competitive salaries, research grants, and professional development opportunities. India can ensure sustained progress in the pharmaceutical sector by supporting its researchers. Universities can set aside research centres to work directly with the industry players. Such collaboration may lead to faster production of drugs and give learners practical skills. Industry-academia can also be a way through which researchers gain access to advanced technology and finance. Reform Regulations for Faster Innovation Use Technology to Speed Up Discoveries Regulatory processes often slow down pharmaceutical research in India. Simplifying clinical trial approvals and protecting intellectual property rights can encourage companies to innovate. Clearer guidance and prompt decisions in these terms will provide a research-friendly environment. Technology has revolutionized pharmaceutical research in the entire globe, and India should adopt it. Artificial intelligence and machine learning can be used for the rapid analysis of data, identification of drug candidates, and prediction of outcomes. Big data analytics can provide insights into disease patterns and treatment effectiveness. The government also needs to favour startups and small companies by simplifying bureaucratic steps. Ease of business research policies will bring global pharmaceuticals to the market and facilitate local entrepreneurship. India has a strong IT sector that can support these technological integrations. From that perspective, India can leverage the synergies between pharma and next-generation technology innovation to accelerate drug development while minimizing costs. That will provide the pharma sector with an edge in global competition. Conclusion India needs to build up pharmaceutical research to combat its healthcare challenges and remain globally competitive. Increasing funding, collaboration, leading-edge technology, and amending regulations can all help shape the research realm in the country. Develop World-class Research Infrastructure Modern infrastructure is a necessary requirement for meaningful progress in pharmaceutical research. The country needs more laboratories equipped with the latest equipment and high-performance computing systems. Dedicated research hubs or special economic zones can provide the space and resources for innovation. Good health is a priority that cannot wait. Investing in pharmaceutical innovation today will pave the way for a healthier and more secure future, which will ensure better care for all. 18 | www.newdelhireview.com 18 | Nov, 2024

22. Leapfrogging Leapfrogging Obstacles Obstacles Pharmaceutical Pharmaceutical T he pharmaceutical sector is possibly one of the most crucial sectors within an economy since it is the part of the economy that paves the way for development in the health sector, and the overall standard of living and faces global health challenges. However, in the pharmaceutical industry, different hurdles hinder the sector from performing optimally in meeting global demands for efficient and affordable medication. The development of India as the emerging pharmaceutical global manufacturing hub and research centre makes the surmounting of such barriers an urgent necessity in the furtherance of growth and innovation. 20 | www.newdelhireview.com 20 | Nov, 2024

23. Challenge Challenge 21 | www.newdelhireview.com Nov, 2024

24. By overcoming the significant challenges to regulation, infrastructure, R&D, and affordability, India can lead the charge toward transforming global healthcare. between academia and the pharmaceutical industry, and insufficient infrastructure for specialized research often bog down progress. 1. Regulatory Challenges Leapfrogging this obstacle requires increased investment in R&D and fostering public-private partnerships. Government policies that incentivize research and provide grants for innovative projects can help overcome financial constraints. Additionally, establishing better collaboration between universities, research institutions, and pharmaceutical companies can foster a culture of innovation. Countries like Israel and Switzerland have already proven that these kinds of collaborative models do work well in advancing medical research, and India can make a success of it, too, by building stronger linkages between academia and industry. The biggest constraint of the Indian pharmaceutical industry is the complicated and sometimes unfriendly regulatory system. Regulatory clearance for new drugs, on the one hand, takes a long time for approval; regulations are not applied equally and the rules differ from state to state or even from institute to institute. Such regulatory hurdles lower the time taken to release new drugs in the market, and thus discourage stakes in research. Infrastructure and supply chain problems should leapfrog and overcome obstacles, streamlined into transparent systems. A single-window approval system, more efficient drug approvals, and greater standards harmonization between regulatory bodies could substantially alleviate these delays. In addition, digitalizing regulatory practices increases transparency decreases paperwork and increases quickness and access for the innovators. 2. Infrastructure and Supply Chain Issues 4. Affordability and Access to Medicines One of the most significant challenges within the pharma industry is affordability, particularly in developing countries like India. India is routinely marketed as a haven for affordable generic medicines, but for the majority of patients, the out-of-pocket costs remain high for complex treatments such as cancer therapies, biological drugs, and newer vaccines. The limitations in infrastructures, such as in logistics and manufacturing, add another obstacle the pharmaceutical industry faces. There is inefficient supply, inefficient transport network, and not enough cold storage for medications that need timely delivery into even remote and hard-to-reach areas to prevent any more lives lost. India has to leapfrog the challenge of investment in low- cost manufacturing processes, enhanced public health expenditure, and control price mechanisms so that essential medications become available to the common people. This would further be promoted through encouraging technology use like telemedicine and mobile health apps so that services in remote areas may also increase. In addition, developing alternative financing models like health insurance and government-sponsored healthcare schemes will definitely bring down the cost burden for patients. To overcome these problems, the pharma industry can use newer technologies like the blockchain and IoT to build more efficient supply chains. Evaluations made with the more efficient cold chain, with enhanced funding of modern production lines, integrated platforms and optimization of communication existing between the manufacturers of the drugs, and logistics providers will further ensure that the needed single reaches its rightful recipient without hitches. Adding automation and Artificial Intelligence to the supply chain will open further possibilities for optimizing operations with reduced costs and improving distribution. The End Note The pharmaceutical industry in India is at the junction, it has great potential in future for revolutionizing the global healthcare sector. This way, India can bypass concerns related to its pharmaceutical industry’s growth including inefficiencies in the regulatory system, infrastructure, R&D investment, and affordability of products to lock itself in the leadership role on the global map. 3. Limitations of R&D India has done reasonably well on the pharmaceutical R&D front but still has far to go because it invests too little in frontier research. India is strong in generic drug manufacturing, but lagging behind in developing new drugs or vaccines. Limited funding, low levels of collaboration 22 | www.newdelhireview.com 22 | Nov, 2024

25. A healthy outside starts the inside. from

28. www.newdelhireview.com